GRIFFIN MICHELLE RENEE sold $1.1M of ADPT
GRIFFIN MICHELLE RENEE sold 52,084 shares of Adaptive Biotechnologies Corp (ADPT) at $20.18 ($1.05M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s open-market sale of $1.05M worth of shares under a pre-arranged 10b5-1 plan is typically not a strong standalone fundamental catalyst.
Market read
Traders may treat this as routine insider activity; any tradable signal is likely small unless it’s part of a broader pattern.
What to watch
The article doesn’t state total insider exposure changes beyond post-transaction holdings, nor whether other insiders filed around the same window.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Adaptive Biotechnologies director Griffin Michelle Renee sold 52,084 shares in an open-market transaction worth about $1.05M, per Form 4.
Low near-term impact; any reaction is likely muted unless follow-on insider activity accelerates.
The filing is a Form 4 insider sale with a stated Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-through; this is company-specific insider liquidity rather than a regulatory/clinical/financing catalyst.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider sales can coincide with valuation or risk concerns; traders may watch for clustering of similar filings.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider sale disclosure.
- insiderGRIFFIN MICHELLE RENEE
Director who sold 52,084 shares at $20.1800/share.